192 related articles for article (PubMed ID: 37627093)
21. Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series.
Chan DL; Pavlakis N; Crumbaker M; Lawrence B; Barber C; Price TJ; Michael M; Oberg K
Asia Pac J Clin Oncol; 2022 Jun; 18(3):209-216. PubMed ID: 33852771
[TBL] [Abstract][Full Text] [Related]
22. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
23. Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features.
Rodríguez Laval V; Pavel M; Steffen IG; Baur AD; Dilz LM; Fischer C; Detjen K; Prasad V; Pascher A; Geisel D; Denecke T
Neuroendocrinology; 2018; 106(2):139-147. PubMed ID: 28384635
[TBL] [Abstract][Full Text] [Related]
24. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality.
Dobson R; Burgess MI; Valle JW; Pritchard DM; Vora J; Wong C; Chadwick C; Keevi B; Adaway J; Hofmann U; Poston GJ; Cuthbertson DJ
Br J Cancer; 2014 Oct; 111(9):1703-9. PubMed ID: 25211656
[TBL] [Abstract][Full Text] [Related]
25. First Case of Regression of Carcinoid Heart Disease on Serial Transthoracic Echocardiograms following Octreotide Monotherapy in a Patient with Metastatic Pancreatic Neuroendocrine Tumor.
Nath E; Sawyer MB; Choy J
Case Rep Oncol; 2020; 13(3):1454-1462. PubMed ID: 33442370
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review.
Kalligeros M; Diamantopoulos L; Toumpanakis C
Biology (Basel); 2021 Sep; 10(10):. PubMed ID: 34681049
[TBL] [Abstract][Full Text] [Related]
27. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Masab M; Saif MW
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1055-1062. PubMed ID: 29051994
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
29. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Martínez-Sáez O; Grande E
Oncologist; 2016 Jun; 21(6):701-7. PubMed ID: 27107003
[TBL] [Abstract][Full Text] [Related]
31. Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration.
Das S; Stockton SS; Hassan SA
Oncologist; 2023 Jul; 28(7):575-583. PubMed ID: 37209415
[TBL] [Abstract][Full Text] [Related]
32. Biochemical Testing in Neuroendocrine Tumors.
Aluri V; Dillon JS
Endocrinol Metab Clin North Am; 2017 Sep; 46(3):669-677. PubMed ID: 28760232
[TBL] [Abstract][Full Text] [Related]
33. The role of N-terminal pro-brain natriuretic peptide, chromogranin A, and 5-hydroxyindoleacetic acid in screening for carcinoid heart disease.
Johnson KKN; Stemann Lau T; Mark Dahl Baunwall S; Elisabeth Villadsen G; Guldbrand Rasmussen V; Grønbaek H; Oksjoki RK; Dam G
J Neuroendocrinol; 2023 Oct; 35(10):e13327. PubMed ID: 37574797
[TBL] [Abstract][Full Text] [Related]
34. Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors.
Cai B; Broder MS; Chang E; Yan T; Metz DC
World J Gastroenterol; 2017 Oct; 23(40):7283-7291. PubMed ID: 29142475
[TBL] [Abstract][Full Text] [Related]
35. Carcinoid tumors of the pancreas. Status report based on two cases and review of the world's literature.
Mao C; el Attar A; Domenico DR; Kim K; Howard JM
Int J Pancreatol; 1998 Apr; 23(2):153-64. PubMed ID: 9629513
[TBL] [Abstract][Full Text] [Related]
36. Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
Sen Gupta P; Grozinsky-Glasberg S; Drake WM; Akker SA; Perry L; Grossman AB; Druce MR
Clin Endocrinol (Oxf); 2014 Feb; 80(2):246-52. PubMed ID: 23790044
[TBL] [Abstract][Full Text] [Related]
37. Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland.
Dobson R; Valle JW; Burgess MI; Poston GJ; Cuthbertson DJ
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):741-6. PubMed ID: 26170123
[TBL] [Abstract][Full Text] [Related]
38. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Halperin DM; Shen C; Dasari A; Xu Y; Chu Y; Zhou S; Shih YT; Yao JC
Lancet Oncol; 2017 Apr; 18(4):525-534. PubMed ID: 28238592
[TBL] [Abstract][Full Text] [Related]
39. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
Johnson PR
Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
[TBL] [Abstract][Full Text] [Related]
40. A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors.
Kjellman M; Knigge U; Welin S; Thiis-Evensen E; Gronbaek H; Schalin-Jäntti C; Sorbye H; Joergensen MT; Johanson V; Metso S; Waldum H; Søreide JA; Ebeling T; Lindberg F; Landerholm K; Wallin G; Salem F; Schneider MDP; Belusa R
Neuroendocrinology; 2021; 111(9):840-849. PubMed ID: 32721955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
